cancer; cellular biophysics; drugs; lung; molecular biophysics; patient treatment; platinum; proteins; tumours; CD3+-CD4+ level; CIK cell transfusion; Karnofsky score; Pt; XiaoJi decoction; clinical efficacy; cytokine-induced killer cells immunotherapy; disease control rate; host cellular immune response; overall response rate; platinum chemotherapy; progression free survival; stage IIIB/IV nonsmall cell lung cancer; treatment related side effects; Cancer; Chemotherapy; Diseases; Immune system; Lungs; Platinum; Tumors; Adjuvant immunotherapy; Cytokine-induced killer cells; Effectiveness; Non-small cell Lung cancer; Xiaoji decoction;
机译:树突状细胞联合细胞因子诱导的杀伤细胞在晚期非小细胞肺癌患者中协同化疗
机译:树突状细胞联合细胞因子诱导的杀伤细胞在晚期非小细胞肺癌患者中协同化疗
机译:新型Plk-1抑制剂BI 2536对IIIB / IV期非小细胞肺癌化疗后复发或失败的患者的疗效和安全性:开放标签,随机II期临床试验的结果。
机译:培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
机译:晚期(IIIB和IV)非小细胞肺癌患者症状管理的评估
机译:患有FDG-PET的SUVMAX的组合预后值和IIIB-IV阶段非小细胞肺癌接受化疗的患者淋巴细胞单核细胞比例
机译:一种临床研究,评估树突和细胞因子诱导的杀手细胞与阶段IIIB非小细胞肺癌同时放射性化学治疗结合